LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 165

Search options

  1. Article: Editorial: Targeting the Wnt/β-catenin signaling pathway in cancer.

    Patergnani, Simone / Buchsbaum, Donald J / Piazza, Gary A

    Frontiers in oncology

    2022  Volume 12, Page(s) 1022174

    Language English
    Publishing date 2022-09-13
    Publishing country Switzerland
    Document type Editorial
    ZDB-ID 2649216-7
    ISSN 2234-943X
    ISSN 2234-943X
    DOI 10.3389/fonc.2022.1022174
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: CD38 pretargeted RIT of B-cell tumors.

    Buchsbaum, Donald J

    Blood

    2018  Volume 131, Issue 6, Page(s) 589–590

    MeSH term(s) Antibodies, Bispecific ; B-Lymphocytes ; Cell Count ; Humans ; Multiple Myeloma ; Radioimmunotherapy
    Chemical Substances Antibodies, Bispecific
    Language English
    Publishing date 2018-02-08
    Publishing country United States
    Document type Journal Article ; Comment
    ZDB-ID 80069-7
    ISSN 1528-0020 ; 0006-4971
    ISSN (online) 1528-0020
    ISSN 0006-4971
    DOI 10.1182/blood-2017-12-819011
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.140: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 364: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Progress in cancer therapy.

    Buchsbaum, Donald J

    Cancer biotherapy & radiopharmaceuticals

    2012  Volume 27, Issue 1, Page(s) 1

    MeSH term(s) Biological Therapy/trends ; Cancer Vaccines/therapeutic use ; Combined Modality Therapy ; Humans ; Medical Oncology/trends ; Neoplasms/drug therapy ; Neoplasms/radiotherapy ; Neoplasms/therapy ; Radiation Oncology/trends ; Radiopharmaceuticals/therapeutic use
    Chemical Substances Cancer Vaccines ; Radiopharmaceuticals
    Language English
    Publishing date 2012-02
    Publishing country United States
    Document type Editorial
    ZDB-ID 1315649-4
    ISSN 1557-8852 ; 1084-9785
    ISSN (online) 1557-8852
    ISSN 1084-9785
    DOI 10.1089/cbr.2012.1201
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1896: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Will detection of microRNA biomarkers in blood improve the diagnosis and survival of patients with pancreatic cancer?

    Buchsbaum, Donald J / Croce, Carlo M

    JAMA

    2014  Volume 311, Issue 4, Page(s) 363–365

    MeSH term(s) Female ; Humans ; Male ; MicroRNAs/blood ; Pancreatic Neoplasms/diagnosis ; Pancreatitis, Chronic/diagnosis
    Chemical Substances MicroRNAs
    Language English
    Publishing date 2014-01-22
    Publishing country United States
    Document type Editorial ; Research Support, N.I.H., Extramural ; Comment
    ZDB-ID 2958-0
    ISSN 1538-3598 ; 0254-9077 ; 0002-9955 ; 0098-7484
    ISSN (online) 1538-3598
    ISSN 0254-9077 ; 0002-9955 ; 0098-7484
    DOI 10.1001/jama.2013.284665
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ua VI Zs.88: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: B7-H3-targeted Radioimmunotherapy of Human Cancer.

    Kasten, Benjamin B / Ferrone, Soldano / Zinn, Kurt R / Buchsbaum, Donald J

    Current medicinal chemistry

    2019  Volume 27, Issue 24, Page(s) 4016–4038

    Abstract: Background: Targeted Radioimmunotherapy (RIT) is an attractive approach to selectively localize therapeutic radionuclides to malignant cells within primary and metastatic tumors while sparing normal tissues from the effects of radiation. Many human ... ...

    Abstract Background: Targeted Radioimmunotherapy (RIT) is an attractive approach to selectively localize therapeutic radionuclides to malignant cells within primary and metastatic tumors while sparing normal tissues from the effects of radiation. Many human malignancies express B7-H3 on the tumor cell surface, while expression on the majority of normal tissues is limited, presenting B7-H3 as a candidate target for RIT. This review provides an overview of the general principles of targeted RIT and discusses publications that have used radiolabeled B7-H3-targeted antibodies for RIT of cancer in preclinical or clinical studies.
    Methods: Databases including PubMed, Scopus, and Google Scholar were searched for publications through June 2018 using a combination of terms including "B7-H3", "radioimmunotherapy", "targeted", "radiotherapy", and "cancer". After screening search results for relevancy, ten publications were included for discussion.
    Results: B7-H3-targeted RIT studies to date range from antibody development and assessment of novel Radioimmunoconjugates (RICs) in animal models of human cancer to phase II/III trials in humans. The majority of clinical studies have used B7-H3-targeted RICs for intra- compartment RIT of central nervous system malignancies. The results of these studies have indicated high tolerability and favorable efficacy outcomes, supporting further assessment of B7-H3-targeted RIT in larger trials. Preclinical B7-H3-targeted RIT studies have also shown encouraging therapeutic outcomes in a variety of solid malignancies.
    Conclusion: B7-H3-targeted RIT studies over the last 15 years have demonstrated feasibility for clinical development and support future assessment in a broader array of human malignancies. Future directions worthy of exploration include strategies that combine B7-H3- targeted RIT with chemotherapy or immunotherapy.
    MeSH term(s) Animals ; Antibodies, Monoclonal ; B7 Antigens ; Humans ; Immunoconjugates ; Immunotherapy ; Neoplasms/therapy ; Radioimmunotherapy
    Chemical Substances Antibodies, Monoclonal ; B7 Antigens ; Immunoconjugates
    Language English
    Publishing date 2019-02-14
    Publishing country United Arab Emirates
    Document type Journal Article ; Review
    ZDB-ID 1319315-6
    ISSN 1875-533X ; 0929-8673
    ISSN (online) 1875-533X
    ISSN 0929-8673
    DOI 10.2174/0929867326666190228120908
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4432: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article: Novel Biomimetic Microphysiological Systems for Tissue Regeneration and Disease Modeling.

    Budhwani, Karim I / Oliver, Patsy G / Buchsbaum, Donald J / Thomas, Vinoy

    Advances in experimental medicine and biology

    2018  Volume 1077, Page(s) 87–113

    Abstract: Biomaterials engineered to closely mimic morphology, architecture, and nanofeatures of naturally occurring in vivo extracellular matrices (ECM) have gained much interest in regenerative medicine and in vitro biomimetic platforms. Similarly, ... ...

    Abstract Biomaterials engineered to closely mimic morphology, architecture, and nanofeatures of naturally occurring in vivo extracellular matrices (ECM) have gained much interest in regenerative medicine and in vitro biomimetic platforms. Similarly, microphysiological systems (MPS), such as lab-chip, have drummed up momentum for recapitulating precise biomechanical conditions to model the in vivo microtissue environment. However, porosity of in vivo scaffolds regulating barrier and interface functions is generally absent in lab-chip systems, or otherwise introduces considerable cost, complexity, and an unrealistic uniformity in pore geometry. We address this by integrating electrospun nanofibrous porous scaffolds in MPS to develop the lab-on-a-brane (LOB) MPS for more effectively modeling transport, air-liquid interface, and tumor progression and for personalized medicine applications.
    MeSH term(s) Biomimetics ; Humans ; Nanofibers ; Regeneration ; Regenerative Medicine ; Tissue Engineering ; Tissue Scaffolds
    Language English
    Publishing date 2018-10-24
    Publishing country United States
    Document type Journal Article
    ISSN 2214-8019 ; 0065-2598
    ISSN (online) 2214-8019
    ISSN 0065-2598
    DOI 10.1007/978-981-13-0947-2_6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article: Epigenetic therapy for the treatment of epithelial ovarian cancer: A clinical review.

    Smith, Haller J / Straughn, J Michael / Buchsbaum, Donald J / Arend, Rebecca C

    Gynecologic oncology reports

    2017  Volume 20, Page(s) 81–86

    Abstract: Despite a good initial response to chemotherapy, the majority of patients with epithelial ovarian cancer will eventually recur and die of their disease. The introduction of targeted therapies to traditional chemotherapy regimens has done little to ... ...

    Abstract Despite a good initial response to chemotherapy, the majority of patients with epithelial ovarian cancer will eventually recur and die of their disease. The introduction of targeted therapies to traditional chemotherapy regimens has done little to improve overall survival in women with ovarian cancer. It has become increasingly apparent that the cancer epigenome contributes significantly to the pathogenesis of ovarian cancer and may play an important role in cell proliferation, metastasis, chemoresistance, and immune tolerance. Epigenetic therapies such as DNA methyltransferase inhibitors and histone deacetylase inhibitors have the potential to reverse these epigenetic changes; however, more research is needed to determine how to incorporate these agents into clinical practice. In this review, we discuss the common epigenetic changes that occur in epithelial ovarian cancer, the current epigenetic therapies that may target these changes, and the clinical experience with epigenetic therapy for the treatment of epithelial ovarian cancer.
    Language English
    Publishing date 2017-03-21
    Publishing country Netherlands
    Document type Journal Article ; Review
    ZDB-ID 2818505-5
    ISSN 2352-5789
    ISSN 2352-5789
    DOI 10.1016/j.gore.2017.03.007
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article: A Novel Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth in Mouse Models of GI Cancer.

    Foote, Jeremy B / Mattox, Tyler E / Keeton, Adam B / Chen, Xi / Smith, Forrest T / Berry, Kristy L / Holmes, Thomas / Wang, Junwei / Huang, Chung-Hui / Ward, Antonio B / Hardy, Cherlene / Fleten, Karrianne G / Flatmark, Kjersti / Yoon, Karina J / Sarvesh, Sujith / Ganji, Puranchandra Nagaraju / Maxuitenko, Yulia / Valiyaveettil, Jacob / Carstens, Julienne L /
    Buchsbaum, Donald J / Yang, Jennifer / Zhou, Gang / Nurmemmedov, Elmar / Babic, Ivan / Gaponenko, Vadim / Abdelkarim, Hazem / Mitra, Amit K / Boyd, Michael R / Manne, Upender / Bae, Sejong / El-Rayes, Bassel F / Piazza, Gary A

    bioRxiv : the preprint server for biology

    2024  

    Abstract: Here we characterize a novel pan-RAS inhibitor, ADT-007, that potently and selectively inhibited the growth of histologically diverse cancer cell lines with mutant or activated RAS irrespective of the RAS mutation or isozyme. Growth inhibition was ... ...

    Abstract Here we characterize a novel pan-RAS inhibitor, ADT-007, that potently and selectively inhibited the growth of histologically diverse cancer cell lines with mutant or activated RAS irrespective of the RAS mutation or isozyme. Growth inhibition was dependent on activated RAS and associated with reduced GTP-RAS levels and MAPK/AKT signaling. ADT-007 bound RAS in lysates from sensitive cells with sub-nanomolar EC
    Significance: ADT-007 is a novel pan-RAS inhibitor with a unique mechanism of action having potential to circumvent resistance to mutant-specific KRAS inhibitors and activate antitumor immunity. The findings support further development of ADT-007 analogs and/or prodrugs with oral bioavailability as a generalizable monotherapy or combined with immunotherapy for RAS mutant cancers.
    Background: It is projected that colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDA) will cause 52,580 and 49,830 deaths in the US in 2023, respectively (1). The 5-year survival rates for CRC and PDA are 65% and 12%, respectively (1). Over 50% of CRC and 90% of PDA patients harbor mutations in KRAS genes that are associated with poor prognosis, making the development of novel KRAS inhibitors an urgent unmet medical need (2).
    Language English
    Publishing date 2024-01-24
    Publishing country United States
    Document type Preprint
    DOI 10.1101/2023.05.17.541233
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  9. Article ; Online: Chapter seven--Cancer treatment with gene therapy and radiation therapy.

    Kaliberov, Sergey A / Buchsbaum, Donald J

    Advances in cancer research

    2012  Volume 115, Page(s) 221–263

    Abstract: Radiation therapy methods have evolved remarkably in recent years which have resulted in more effective local tumor control with negligible toxicity of surrounding normal tissues. However, local recurrence and distant metastasis often occur following ... ...

    Abstract Radiation therapy methods have evolved remarkably in recent years which have resulted in more effective local tumor control with negligible toxicity of surrounding normal tissues. However, local recurrence and distant metastasis often occur following radiation therapy mostly due to the development of radioresistance through the deregulation of the cell cycle, apoptosis, and inhibition of DNA damage repair mechanisms. Over the last decade, extensive progress in radiotherapy and gene therapy combinatorial approaches has been achieved to overcome resistance of tumor cells to radiation. In this review, we summarize the results from experimental cancer therapy studies on the combination of radiation therapy and gene therapy.
    MeSH term(s) Animals ; Apoptosis ; Clinical Trials as Topic ; Combined Modality Therapy/methods ; DNA Repair ; Gene Transfer Techniques ; Genetic Therapy/methods ; Humans ; Medical Oncology/trends ; Neoplasms/genetics ; Neoplasms/radiotherapy ; Neoplasms/therapy ; Promoter Regions, Genetic ; Radiotherapy/methods ; Response Elements ; Signal Transduction
    Language English
    Publishing date 2012-09-29
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Review
    ZDB-ID 127-2
    ISSN 2162-5557 ; 0065-230X
    ISSN (online) 2162-5557
    ISSN 0065-230X
    DOI 10.1016/B978-0-12-398342-8.00007-0
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.178: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Corrigendum to '

    Kasten, Benjamin B / Gangrade, Abhishek / Kim, Harrison / Fan, Jinda / Ferrone, Soldano / Ferrone, Cristina R / Zinn, Kurt R / Buchsbaum, Donald J

    Nuclear medicine and biology

    2018  Volume 61, Page(s) 71

    Language English
    Publishing date 2018-04-25
    Publishing country United States
    Document type Journal Article ; Published Erratum
    ZDB-ID 1138098-6
    ISSN 1872-9614 ; 0883-2897 ; 0969-8051
    ISSN (online) 1872-9614
    ISSN 0883-2897 ; 0969-8051
    DOI 10.1016/j.nucmedbio.2018.03.004
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1090: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top